COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study
Gary T Ferguson,1 Mo Ghafouri,2 Luyan Dai,2 Leonard J Dunn3
1Pulmonary Research Institute of Southeast Michigan, Livonia, MI, USA; 2Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA; 3Clinical Research of West Florida, Inc, Clearwater, FL, USA
Background: Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant.
Objective: The objective of this study was to evaluate patient satisfaction, device usage, and long-term safety of CVT-R compared to CVT-MDI, and to the simultaneous administration of ipratropium bromide hydrofluoroalkane (HFA; I) and albuterol HFA (A) metered-dose inhalers as dual monotherapies (I + A).
Design: This is a 48-week, open-label, randomized, active-controlled, parallel-group study (n = 470) comparing CVT-R to CVT-MDI and to I + A.
Participants: Patients were at least 40 years of age, diagnosed with chronic obstructive pulmonary disease (COPD), and current or exsmokers.
Interventions: Patients were randomized to receive: (1) CVT-R, one inhalation four times daily (QID); or (2) CVT-MDI, two inhalations QID; or (3) I + A two inhalations of each inhaler QID.
Main measures: Patient Satisfaction and Preference Questionnaire (PASAPQ) performance score (primary endpoint) and adverse events.
Key results: PASAPQ performance score was significantly higher (CVT-R versus CVT-MDI, 9.6; and CVT-R versus I + A, 6.2; both P < 0.001) when using CVT-R compared to CVT-MDI or I + A at all visits starting from week 3, while CVT-MDI and I + A treatment groups were similar. Time to first COPD exacerbation was slightly longer in the CVT-R group compared to the other treatment groups, although it did not reach statistical significance (CVT-R versus CVT-MDI, P = 0.57; CVT-R versus I + A, P = 0.22). Rates of withdrawal and patient refusal to continue treatment were lower in CVT-R compared with CVT-MDI and I + A groups (CVT-R versus CVT-MDI, P = 0.09; CVT-R versus I + A, P = 0.005). The percentage of patients reporting adverse events and serious adverse events was similar across all three treatment groups.
Conclusion: CVT-R is an effective, environmentally friendly inhaler that provides patients with a high level of user satisfaction and may positively impact clinical outcomes while having no adverse impacts on patients using the device.
Keywords: COPD, consumer satisfaction, consumer preference, inhalers
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other articles by this author:
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R
Published Date: 31 October 2016
Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P
Published Date: 16 June 2014
Readers of this article also read:
Antimicrobial activity of cream incorporated with silver nanoparticles biosynthesized from Withania somnifera
Marslin G, Selvakesavan RK, Franklin G, Sarmento B, Dias ACP
Published Date: 22 September 2015
Sievi NA, Franzen D, Kohler M, Clarenbach CF
Published Date: 10 September 2015
A novel diblock copolymer of (monomethoxy poly [ethylene glycol]-oleate) with a small hydrophobic fraction to make stable micelles/polymersomes for curcumin delivery to cancer cells
Erfani-Moghadam V, Nomani A, Zamani M, Yazdani Y, Najafi F, Sadeghizadeh M
Published Date: 28 November 2014
Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C
Published Date: 1 September 2014
Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease
Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM
Published Date: 9 July 2014
Marques C, Ferreira JMF, Andronescu E, Ficai D, Sonmez M, Ficai A
Published Date: 28 May 2014
Campani V, Marchese D, Pitaro MT, Pitaro M, Grieco P, De Rosa G
Published Date: 10 April 2014
Indirect costs in chronic obstructive pulmonary disease: A review of the economic burden on employers and individuals in the United States
Patel JG, Nagar SP, Dalal AA
Published Date: 19 March 2014
Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, Ribeiro F, Saey D
Published Date: 15 February 2014
P-wave indices in patients with pulmonary emphysema: do P-terminal force and interatrial block have confounding effects?
Chhabra L, Chaubey VK, Kothagundla C, Bajaj R, Kaul S, Spodick DH
Published Date: 14 May 2013